Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Director Sells 18,000 Shares of Company Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Kristine Ball sold 18,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $104.93, for a total value of $1,888,740.00. Following the sale, the director directly owned 18,000 shares in the company, valued at approximately $1,888,740. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oruka Therapeutics Trading Up 0.3%

ORKA traded up $0.36 on Friday, hitting $105.35. 679,678 shares of the stock traded hands, compared to its average volume of 1,033,539. Oruka Therapeutics, Inc. has a 52 week low of $25.23 and a 52 week high of $115.51. The business has a fifty day moving average price of $89.68 and a two-hundred day moving average price of $72.36.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current year.

Oruka Therapeutics News Summary

Investors following ORKA have been watching these news items:

• Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
• Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
• Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of recent research reports. Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Wedbush reiterated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Monday, October 26th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $141.80.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of ORKA. BlackRock Inc. acquired a new position in shares of Oruka Therapeutics in the 2nd quarter worth approximately $474,916,000. Jupiter Topco LLC bought a new position in shares of Oruka Therapeutics during the 2nd quarter worth approximately $130,968,000. Bank of America Corp DE acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at $33,578,000. Braidwell LP acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at $26,473,000. Finally, Atika Capital Management LLC acquired a new stake in Oruka Therapeutics in the 1st quarter valued at $11,277,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.